Syndax Pharmaceuticals Inc. (SNDX) said that it has priced an underwritten public offering of about 6.82 million shares of its common stock at $22.00 per share.
The aggregate gross proceeds from the offering are expected to be approximately $150.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Syndax.
In addition, Syndax granted the underwriters a 30-day option to purchase up to an additional 1.02 million shares of common stock. The offering is expected to close on December 9, 2022, subject to customary closing conditions.
For comments and feedback contact: editorial@rttnews.com
Business News